Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome
about
A chemocentric approach to the identification of cancer targetsPrediction of the P. falciparum target space relevant to malaria drug discoveryOf possible cheminformatics futures.Polypharmacology in Precision Oncology: Current Applications and Future ProspectsData Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson SyndromeFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes.Drug Repurposing from an Academic Perspective.Drug repurposing: far beyond new targets for old drugs.Systems approaches in risk assessment.Design of a general-purpose European compound screening library for EU-OPENSCREEN.A Case of Fatal Serotonin Syndrome-Like Human Rabies Caused by Tricolored Bat-Associated Rabies Virus.Myxobacteria: natural pharmaceutical factories.The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.Maternal use of cyclobenzaprine (Flexeril) may induce ductal closure and persistent pulmonary hypertension in neonates.A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.Synthesis, pharmacological evaluation and molecular docking of pyranopyrazole-linked 1,4-dihydropyridines as potent positive inotropes.Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis.On the origins of drug polypharmacology
P2860
Q28482507-15612B5F-B492-4DDF-A7C4-2DF7A09BB4CFQ28534474-717F2897-7FFE-419A-958C-19E630925610Q30485257-749F0384-5816-44F0-967E-BFB14109ACDEQ30846907-05FB25E8-FD5B-44AD-A5E0-E1BD3F4E0CC3Q30932631-BC384188-0B36-4334-8B9F-7EFF76BF549AQ34646772-416706E1-2D71-4F77-9E52-BFEC7FE3D07AQ35453774-EABE7F15-9F47-4B8C-8E95-F8B4128A319CQ35774211-6DB08C80-1170-4C68-A702-8400E1FD396BQ36331528-7313DC8A-CF7A-4807-82F3-CE401A4D292AQ38093360-DEECDE51-1EB2-44C4-9C85-902E04B3A5E9Q39156659-FD39BD57-3FD3-4514-8C50-683D6D83AA7AQ40746168-EDE4DC8E-B855-4240-A0D1-094D26B6617EQ41984192-69E7268D-7772-43F9-9158-DA89BA239E96Q42679414-0308EFE3-886D-45A2-AFE0-AE7BBCC59E5DQ44137776-2927101F-E299-457E-91FF-AD9FD3663EBDQ52641632-C96C1C08-FE1D-4F29-AF0E-7CAEE021BE25Q53113337-48E48E6F-4709-476A-843B-6BEBC1C03115Q55308829-BE82A578-E208-495F-A394-E3462A955416Q57012617-E3FFD5FB-90C8-42C8-8146-F631FE1E73BF
P2860
Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Linking pharmacology to clinic ...... iation with serotonin syndrome
@en
Linking pharmacology to clinic ...... ation with serotonin syndrome.
@nl
type
label
Linking pharmacology to clinic ...... iation with serotonin syndrome
@en
Linking pharmacology to clinic ...... ation with serotonin syndrome.
@nl
prefLabel
Linking pharmacology to clinic ...... iation with serotonin syndrome
@en
Linking pharmacology to clinic ...... ation with serotonin syndrome.
@nl
P2860
P50
P356
P1476
Linking pharmacology to clinic ...... iation with serotonin syndrome
@en
P2093
S A Seifert
P2860
P304
P356
10.1038/CLPT.2011.177
P407
P577
2011-10-05T00:00:00Z